Drugs / Enteric-coated mycophenolate sodium
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00284934 | Dec 2005 → Jun 2008 | kidney disorder | Novartis | Completed | Met primary |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT00862979 | Feb 2009 → Mar 2017 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT00443937 | Jan 2004 → Mar 2006 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT03663335 Background | Nov 2018 → Oct 2021 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04877288 Background | Jul 2021 → Dec 2032 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 4 | NCT00522548 Comparator | Mar 2007 → Jan 2011 | — | University of Pennsylvania | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00154310 Background | Jun 2005 → Sep 2008 | — | Novartis | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enteric coated mycophenolate sodium | “Enteric-coated mycophenolate sodium (EC-MPS)” NCT03663335 ↗ |
| Known as | EC-MPS | “Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus” NCT00284934 ↗1“Enteric-coated mycophenolate sodium (EC-MPS)” NCT03663335 ↗ |
| Route | Oral | “Enteric-coated mycophenolate sodium orally twice a day” NCT00154310 ↗ |